Clinical trial documentation rarely stays unchanged from study startup to closeout. Protocols are amended, patient materials are updated, and country-specific requirements must be addressed as a study progresses. When several languages are involved, each change can affect more than one document, team, or submission.

For sponsors and contract research organizations (CROs), clinical trial translation is therefore more than a matter of converting documents into another language. It requires careful planning, terminology management, version control, and quality checks suited to the purpose of each document.

A well-organized translation process cannot eliminate every risk, but it can help teams identify inconsistencies, manage revisions, and prepare multilingual documentation more reliably.

1. Identify Which Documents Need Translation

Before requesting a quotation or setting a delivery date, establish exactly what needs to be translated and why.

Clinical trials can involve different types of documentation, including:

• Study protocols and protocol amendments
• Informed consent forms and patient information sheets
• Participant recruitment materials
• Investigator and site-facing instructions
• Patient questionnaires and diaries
• Safety-related communications
• Study correspondence and other supporting documents

Not every document requires the same translation approach. The intended audience, applicable requirements, and consequences of an error should determine the level of expertise and review needed.

For example, a document intended for a regulatory submission may have different requirements from instructions that participants must read and follow. Some documents may also require additional medical, regulatory, or local review.

Practical check: Prepare a document inventory that identifies the source language, target languages, intended users, document versions, deadlines, and any specific approval requirements.

2. Check Country-Specific Language Requirements Early

One of the most important planning questions is whether a particular document must be submitted or provided in a specific language.

In the European Union, Regulation (EU) No 536/2014 establishes that the Member State concerned determines the language of the clinical trial application dossier, or relevant parts of it. The regulation also provides for consideration of a commonly understood medical language for documentation not addressed to trial participants.

This distinction matters for multinational studies. Requirements may differ between participating countries and between document categories.

The European Commission maintains guidance and country-specific information through EudraLex Volume 10, including the Clinical Trials Regulation questions-and-answers document. Sponsors should consult the current guidance and relevant national requirements when planning submissions.

Practical check: Confirm language requirements for each participating country before finalizing the translation scope. Do not assume that an approach accepted in one country will be appropriate in another.

3. Treat Patient-Facing Documents as a Distinct Workstream

Patient-facing materials require particular attention because they are intended to communicate information to people who may not have a medical background.

An informed consent form, for example, must communicate important information about study participation without changing the intended meaning. Technical accuracy is essential, but terminology that is appropriate for healthcare professionals may not be readily understood by prospective participants.

The translation process should consider:

• Whether medical terms are accurate and understandable
• Whether risks, procedures, and participant responsibilities are described consistently
• Whether dates, numbers, and instructions are unambiguous
• Whether the wording is appropriate for the intended readership
• Whether the document requires additional review under the study’s procedures or applicable requirements

Translation is only one part of effective participant communication. The broader informed consent process remains the responsibility of the appropriate study personnel.

ICH E6(R3) İyi Klinik Uygulamalar kılavuzu, klinik araştırmaların yürütülmesinde katılımcıların korunmasını ve bilgilendirilmiş onamın önemini vurgular.

Practical check: Identify patient-facing documents separately in the translation plan and define who will assess their medical accuracy, readability, and final suitability for use.

4. Establish Terminology Before Translation Begins

Clinical trial documentation often contains terminology that must remain consistent across multiple documents and updates.

A study may use the same terms in the protocol, consent form, investigator instructions, and participant materials. If different translators choose different equivalents, the resulting inconsistencies can create confusion and additional review work.

A project-specific terminology glossary can help prevent this.

It should include approved terminology, relevant abbreviations, product and study names, and any wording that must remain unchanged. Where appropriate, it should also distinguish between technical terminology used by professionals and patient-friendly expressions.

Terminology decisions should be reviewed by the appropriate subject-matter experts rather than left entirely to individual translator preference.

Practical check: Agree on a glossary and reference materials at the beginning of the project, then maintain them as the study develops.

5. Plan for Protocol Amendments and Document Updates

An approved translation may need to be revised when the source document changes.

Protocol amendments, updates to patient materials, or changes to study procedures can affect terminology and content across several files. Without clear version control, teams may struggle to identify which translation corresponds to the latest approved source.

A controlled process should record the source version, translated version, language, date, and approval status of each document.

Where appropriate, translation memory tools and comparison files can help identify previously translated material and changed passages. However, repeated wording still needs to be checked in context. A sentence that remains unchanged may require attention if the surrounding instructions have been revised.

Practical check: Establish how source changes will be communicated, how affected translations will be identified, and who will approve revised documents before they are used.

6. Define Quality Checks According to Document Risk

A single quality-control method is unlikely to be suitable for every clinical trial document.

The appropriate process depends on the document’s purpose, complexity, audience, and applicable requirements.

For higher-impact material, checks may include comparison against the source, verification of medical terminology, review of numbers and instructions, and assessment by an appropriately qualified subject-matter expert.

Formatting also deserves attention. Tables, footnotes, checkboxes, and references can affect how information is interpreted, particularly when translated content is incorporated into forms or templates.

A structured review should distinguish between linguistic accuracy, subject-matter accuracy, and final document approval. These activities may involve different people.

Practical check: Define the required checks and responsibilities for each document category before work begins, rather than relying on an undefined final review.

7. Include Confidentiality and Data Handling in Vendor Selection

Clinical trial materials may contain confidential research information, commercially sensitive data, or personal information.

Before transferring files, sponsors and CROs should understand how their translation partner receives, stores, processes, and shares project information.

Relevant questions include whether access is restricted to authorized personnel, which tools are used, whether subcontractors are involved, and how confidentiality and data protection obligations are addressed.

The use of artificial intelligence or machine translation should also be considered within these requirements. A tool’s ability to produce fluent text does not establish that it is suitable for handling a particular document or dataset.

Practical check: Confirm data-handling arrangements and any restrictions on translation technologies before sending confidential materials.

8. Give Translation Teams the Context They Need

A translation brief should provide more than a file and a deadline.

Translators and reviewers may need to understand the therapeutic area, study phase, intended audience, document purpose, and relevant terminology. They should also have a clear route for raising questions when the source is ambiguous.

Sponsors and CROs can support the process by supplying approved reference documents, identifying the people responsible for answering queries, and communicating changes promptly.

This is especially valuable in projects involving several countries, languages, and review teams.

Practical check: Assign a contact for terminology and content questions, define review timelines, and establish how feedback will be consolidated.

Clinical Trial Translation Checklist

A More Reliable Approach to Multilingual Clinical Trials

Clinical trial translation works best when it is planned as part of study documentation management rather than treated as a final administrative task.

Clear document inventories, early confirmation of language requirements, consistent terminology, controlled revisions, and appropriate quality checks help sponsors and CROs manage multilingual work with greater confidence.

An experienced medical translation partner can support this process by coordinating qualified language specialists, maintaining terminology resources, managing document updates, and applying agreed quality procedures.

The objective is not simply to deliver translated files. It is to provide accurate, consistent, and usable documentation that meets the project’s defined needs.